Compare BGB & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGB | DNA |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 607.1M |
| IPO Year | N/A | N/A |
| Metric | BGB | DNA |
|---|---|---|
| Price | $11.66 | $9.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 154.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,606,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.40 | $5.00 |
| 52 Week High | $11.97 | $17.58 |
| Indicator | BGB | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 49.75 |
| Support Level | $11.52 | $8.65 |
| Resistance Level | $11.77 | $10.38 |
| Average True Range (ATR) | 0.08 | 0.78 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 38.00 | 57.36 |
Blackstone Strategic Credit Fund is a closed-end term fund. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.